Biomarkers and Updates on Pediatrics Lupus Nephritis

Rheumatic Disease Clinics of North America

Volumn 39, Issue 4, 2013, Pages 833-853

  Bennett, Michael ^a   Brunner, Hermine I ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Biomarkers; Childhood onset SLE; Lupus nephritis; Systemic lupus erythematosus; Treatment

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CERULOPLASMIN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT COMPONENT C4D; CREATININE; CXCL16 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPCIDIN; LIPOCALIN TYPE PROSTAGLANDIN D SYNTHASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OROSOMUCOID; PROSTAGLANDIN D SYNTHASE; TRANSFERRIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORLIKE WEAK INDUCER OF APOPTOSIS PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL FEATURE; COST OF ILLNESS; CREATININE URINE LEVEL; DISEASE CLASSIFICATION; DISEASE MARKER; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE SEDIMENT;

BIOMARKERS; CHILDHOOD-ONSET SLE; LUPUS NEPHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; BIOPSY; CHEMOKINE CCL2; CHILD; COMPLEMENT C4; GLUCOCORTICOIDS; HEPCIDINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LIPOCALINS; LUPUS NEPHRITIS; PROTEINURIA; PROTO-ONCOGENE PROTEINS; TUMOR NECROSIS FACTORS;

EID: 84886791407     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.05.001     Document Type: Review

References (147)

1. Silva C.A., Avcin T., Brunner H.I. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken) 2012, 64(12):1787-1793.
2. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15(5):308-318.
3. Hiraki L.T., Feldman C.H., Liu J., et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 2012, 64(8):2669-2676.
4. Aletaha D., Landewe R., Karonitsch T., et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008, 59(10):1371-1377.
5. Livingston B., Bonner A., Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011, 20(13):1345-1355.
6. Hiraki L.T., Lu B., Alexander S.R., et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum 2011, 63(7):1988-1997.
7. Bernatsky S., Boivin J.F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2550-2557.
8. Lionaki S., Kapitsinou P.P., Iniotaki A., et al. Kidney transplantation in lupus patients:a case-control study from a single centre. Lupus 2008, 17(7):670-675.
9. Pereira T., Abitbol C.L., Seeherunvong W., et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol 2011, 6(9):2192-2199.
10. Costenbader K.H., Desai A., Alarcon G.S., et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011, 63(6):1681-1688.
11. Tanzer M., Tran C., Messer K.L., et al. Inpatient health care utilization by children and adolescents with systemic lupus erythematosus and kidney involvement. Arthritis Care Res (Hoboken) 2013, 65(3):382-390.
12. Brunner H.I., Sherrard T.M., Klein-Gitelman M.S. Cost of treatment of childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006, 55(2):184-188.
13. NAPRTCS. North American Pediatric Renal Trials and Collaborative Studies Annual Report. 2011. Available at: http://https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
14. Bertsias G.K., Tektonidou M., Amoura Z., et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012, 71(11):1771-1782.
15. Hollander M.C., Sage J.M., Greenler A.J., et al. International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2013, [Epub ahead of print].
16. Marks S.D., Sebire N.J., Pilkington C., et al. Clinicopathological correlations of paediatriclupus nephritis. Pediatr Nephrol 2007, 22(1):77-83.
17. Brunner H.I., Gladman D.D., Ibanez D., et al. Difference in disease features betweenchildhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008, 58(2):556-562.
18. Hiraki L.T., Benseler S.M., Tyrrell P.N., et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. JPediatr 2008, 152(4):550-556.
19. Ruggiero B., Vivarelli M., Gianviti A., et al. Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrol Dial Transplant 2013, 28(6):1487-1496.
20. Weening J.J., D'Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. JAm Soc Nephrol 2004, 15(2):241-250.
21. Corwin H.L., Schwartz M.M., Lewis E.J. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol 1988, 8(2):85-89.
22. Austin H.A., Muenz L.R., Joyce K.M., et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984, 25(4):689-695.
23. Hsieh C., Chang A., Brandt D., et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 2011, 63(6):865-874.
24. Cortes-Hernandez J., Ordi-Ros J., Labrador M., et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003, 12(4):287-296.
25. Zappitelli M., Duffy C., Bernard C., et al. Clinicopathological study of the WHOclassification in childhood lupus nephritis. Pediatr Nephrol 2004, 19(5):503-510.
26. Lee B.S., Cho H.Y., Kim E.J., et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007, 22(2):222-231.
27. Demircin G., Oner A., Erdogan O., et al. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis. Ren Fail 2008, 30(6):603-609.
28. Hagelberg S., Lee Y., Bargman J., et al. Longterm followup of childhood lupus nephritis. JRheumatol 2002, 29(12):2635-2642.
29. Vachvanichsanong P., Dissaneewate P., McNeil E. Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood onset lupus nephritis: a 23-year experience in a single centre. Nephrol Dial Transplant 2009, 24(9):2729-2734.
30. Hersh A.O., von Scheven E., Yazdany J., et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009, 61(1):13-20.
31. Zappitelli M., Duffy C.M., Bernard C., et al. Evaluation of activity, chronicity and tubulointerstitialindices for childhood lupus nephritis. Pediatr Nephrol 2008, 23(1):83-91.
32. Chrysochou C., Randhawa H., Reeve R., et al. Determinants of renal functional outcome in lupus nephritis: a single centre retrospective study. QJM 2008, 101(4):313-316.
33. Contreras G., Pardo V., Cely C., et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005, 14(11):890-895.
34. Houssiau F.A. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther 2012, 14(1):202.
35. Mok C.C., Ying K.Y., Tang S., et al. Predictors and outcome of renal flares after successfulcyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004, 50(8):2559-2568.
36. Punaro M., Abou-Jaoude P., Cimaz R., et al. Unusual neurologic manifestations (II): posterior reversible encephalopathy syndrome (PRES) in the context of juvenilesystemic lupus erythematosus. Lupus 2007, 16(8):576-579.
37. Valente de Almeida R., Rocha de Carvalho J.G., de Azevedo V.F., et al. Microalbuminuria and renal morphology in the evaluation of subclinical lupus nephritis. Clin Nephrol 1999, 52(4):218-229.
38. Houssiau F.A., Vasconcelos C., D'Cruz D., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004, 50(12):3934-3940.
39. Eddy A.A., Giachelli C.M. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995, 47(6):1546-1557.
40. Siedner M.J., Gelber A.C., Rovin B.H., et al. Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. JRheumatol 2008, 35(1):84-90.
41. Hebert L.A., Birmingham D.J., Shidham G., et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemiclupus erythematosus nephritis patients. Nephron Clin Pract 2009, 113(3):c177-c182.
42. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49(2 Suppl 2):S12-S154.
43. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006, 54(2):421-432.
44. Fine D.M., Ziegenbein M., Petri M., et al. Aprospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. KidneyInt 2009, 76(12):1284-1288.
45. Fogazzi G.B., Garigali G. The clinical art and science of urine microscopy. Curr Opin Nephrol Hypertens 2003, 12(6):625-632.
46. Bacchetta J., Cochat P., Rognant N., et al. Which creatinine and cystatin C equations can be reliably used in children?. Clin J Am Soc Nephrol 2011, 6(3):552-560.
47. Lertnawapan R., Bian A., Rho Y.H., et al. Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus. Lupus 2012, 21(3):279-287.
48. Chew C., Pemberton P.W., Husain A.A., et al. Serum cystatin C is independently associated with renal impairment and high sensitivity C-reactive protein in systemiclupus erythematosus. Clin Exp Rheumatol 2013, 31(2):251-255.
49. Christopher-Stine L., Siedner M., Lin J., et al. Renal biopsy in lupus patients with low levels of proteinuria. JRheumatol 2007, 34(2):332-335.
50. Vernon K.A., Cook H.T. Complement in glomerular disease. Adv Chronic Kidney Dis 2012, 19(2):84-92.
51. Rovin B.H., Birmingham D.J., Nagaraja H.N., et al. Biomarker discovery in human SLE nephritis. Bull N Y U Hosp Jt Dis 2007, 65(3):187-193.
52. Ho A., Barr S.G., Magder L.S., et al. Adecrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44(10):2350-2357.
53. Esdaile J.M., Abrahamowicz M., Joseph L., et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996, 39(3):370-378.
54. Suzuki M., Wiers K., Brooks E.B., et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res 2009, 65(5):530-536.
55. Grootscholten C., Bajema I.M., Florquin S., et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant 2008, 23(1):223-230.
56. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
57. Devarajan P. Proteomics for biomarker discovery in acute kidney injury. Semin Nephrol 2007, 27(6):637-651.
58. Knepper M.A. Proteomics and the kidney. JAm Soc Nephrol 2002, 13(5):1398-1408.
59. Thongboonkerd V., McLeish K.R., Arthur J.M., et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002, 62(4):1461-1469.
60. Adachi J., Kumar C., Zhang Y., et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006, 7(9):R80.
61. Omenn G.S. Exploring the human plasma proteome. Proteomics 2005, 5(13):3223-3225.
62. Omenn G.S., States D.J., Adamski M., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5(13):3226-3245.
63. States D.J., Omenn G.S., Blackwell T.W., et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006, 24(3):333-338.
64. D'Alessandro A., Righetti P.G., Zolla L. The Red Blood Cell proteome and interactome:an update. JProteome Res 2010, 9(1):144-163.
65. van Gestel R.A., van Solinge W.W., van der Toorn H.W., et al. Quantitative erythrocyte membrane proteome analysis with Blue-Native/SDS PAGE. JProteomics 2010, 73(3):456-465.
66. Knepper M.A. Common sense approaches to urinary biomarker study design. JAm Soc Nephrol 2009, 20(6):1175-1178.
67. Hewitt S.M., Dear J., Star R.A. Discovery of protein biomarkers for renal diseases. JAm Soc Nephrol 2004, 15(7):1677-1689.
68. Dos Remedios C.G., Liew C.C., Allen P.D., et al. Genomics, proteomics and bioinformatics of human heart failure. JMuscle Res Cell Motil 2003, 24(4-6):251-260.
69. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39(4):561-577.
70. Rovin B.H. The chemokine network in systemic lupus erythematous nephritis. Front Biosci 2008, 13:904-922.
71. Hasegawa H., Kohno M., Sasaki M., et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003, 48(9):2555-2566.
72. Kulkarni O., Pawar R.D., Purschke W., et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. JAm Soc Nephrol 2007, 18(8):2350-2358.
73. Rovin B.H., Song H., Birmingham D.J., et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. JAm Soc Nephrol 2005, 16(2):467-473.
74. Kiani A.N., Johnson K., Chen C., et al. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. JRheumatol 2009, 36(10):2224-2230.
75. Tucci M., Barnes E.V., Sobel E.S., et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004, 50(6):1842-1849.
76. Watson L., Midgley A., Pilkington C., et al. Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 2012, 21(5):496-501.
77. Wu T., Xie C., Wang H.W., et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. JImmunol 2007, 179(10):7166-7175.
78. Graves D.T., Alsulaimani F., Ding Y., et al. Developmentally regulated monocyte recruitment and bone resorption are modulated by functional deletion of the monocytic chemoattractant protein-1 gene. Bone 2002, 31(2):282-287.
79. Zhang X., Jin M., Wu H., et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 2008, 74(6):799-807.
80. Tian S., Li J., Wang L., et al. Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res 2007, 56(7):304-310.
81. Chan R.W., Lai F.M., Li E.K., et al. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant 2006, 21(6):1534-1540.
82. Gharaee-Kermani M., Denholm E.M., Phan S.H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. JBiol Chem 1996, 271(30):17779-17784.
83. Sakai N., Wada T., Furuichi K., et al. MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. JLeukoc Biol 2006, 79(3):555-563.
84. Rovin B.H. Chemokines as therapeutic targets in renal inflammation. Am J KidneyDis 1999, 34(4):761-764. [discussion: 765-7].
85. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365(9466):1231-1238.
86. Mishra J., Ma Q., Kelly C., et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol (Berlin, Germany) 2006, 21(6):856-863.
87. Mishra J., Mori K., Ma Q., et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004, 24(3):307-315.
88. Bennett M., Dent C.L., Ma Q., et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008, 3(3):665-673.
89. Haase M., Bellomo R., Devarajan P., et al. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg 2009, 88(1):124-130.
90. Krawczeski C.D., Goldstein S.L., Woo J.G., et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. JAm Coll Cardiol 2011, 58(22):2301-2309.
91. Krawczeski C.D., Woo J.G., Wang Y., et al. Neutrophil gelatinase-associated lipocalinconcentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. JPediatr 2011, 5:5.
92. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009, 32(2):91-98.
93. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(2):337-344.
94. Bennett M.R., Piyaphanee N., Czech K., et al. NGAL distinguishes steroid sensitivity in idiopathic nephrotic syndrome. Pediatr Nephrol (Berlin, Germany) 2012, 27(5):807-812.
95. Brunner H.I., Mueller M., Rutherford C., et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2577-2584.
96. Hinze C.H., Suzuki M., Klein-Gitelman M., et al. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemiclupus erythematosus disease activity. Arthritis Rheum 2009, 60(9):2772-2781.
97. Pitashny M., Schwartz N., Qing X., et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007, 56(6):1894-1903.
98. Suzuki M., Wiers K.M., Klein-Gitelman M.S., et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008, 23(3):403-412.
99. Ivashkiv L.B. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 2003, 36(8):473-479.
100. Tackey E., Lipsky P.E., Illei G.G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004, 13(5):339-343.
101. Zhang X., Rovin B.H. Hepcidin expression by human monocytes in response to adhesion and pro-inflammatory cytokines. Biochim Biophys Acta 2010, 1800(12):1262-1267.
102. Suzuki M., Ross G.F., Wiers K., et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol 2007, 22(12):2047-2057.
103. Batal I., Liang K., Bastacky S., et al. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study. Lupus 2012, 21(1):13-26.
104. Li S.J., Liu Z.H., Zen C.H., et al. Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection. Lupus 2007, 16(11):875-880.
105. Cohen D., Koopmans M., Kremer Hovinga I.C., et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 2008, 58(8):2460-2469.
106. Dhir V. Is cellular C4d a good biomarker for SLE nephritis?. Lupus 2012, 21(9):1036.
107. Liu C.C., Manzi S., Kao A.H., et al. Reticulocytes bearing C4d as biomarkers of diseaseactivity for systemic lupus erythematosus. Arthritis Rheum 2005, 52(10):3087-3099.
108. Navratil J.S., Manzi S., Kao A.H., et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006, 54(2):670-674.
109. Edelbauer M., Kshirsagar S., Riedl M., et al. Activity of childhood lupus nephritis is linked to altered T cell and cytokine homeostasis. JClin Immunol 2012, 32(3):477-487.
110. Campbell S., Michaelson J., Burkly L., et al. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004, 9:2273-2284.
111. Campbell S., Burkly L.C., Gao H.X., et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. JImmunol 2006, 176(3):1889-1898.
112. Reyes-Thomas J., Blanco I., Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011, 40(3):138-150.
113. Schwartz N., Michaelson J.S., Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 2007, 1109:265-274.
114. Schwartz N., Su L., Burkly L.C., et al. Urinary TWEAK and the activity of lupus nephritis. JAutoimmun 2006, 27(4):242-250.
115. Schwartz N., Rubinstein T., Burkly L.C., et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009, 11(5):R143.
116. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. NEngl J Med 1998, 338(7):436-445.
117. Bauer J.W., Baechler E.C., Petri M., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006, 3(12):e491.
118. Avihingsanon Y., Phumesin P., Benjachat T., et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006, 69(4):747-753.
119. Wang G., Lai F.M., Tam L.S., et al. Urinary FOXP3 mRNA in patients with lupus nephritis-relation with disease activity and treatment response. Rheumatology (Oxford) 2009, 48(7):755-760.
120. Valencia X., Yarboro C., Illei G., et al. Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. JImmunol 2007, 178(4):2579-2588.
121. McHale J.F., Harari O.A., Marshall D., et al. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. JImmunol 1999, 163(7):3993-4000.
122. Alon R., Kassner P.D., Carr M.W., et al. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. JCell Biol 1995, 128(6):1243-1253.
123. Kiani A.N., Wu T., Fang H., et al. Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. JRheumatol 2012, 39(6):1231-1237.
124. Abd-Elkareem M.I., Al Tamimy H.M., Khamis O.A., et al. Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin Exp Nephrol 2010, 14(6):548-557.
125. Ikeda Y., Fujimoto T., Ameno M., et al. Relationship between lupus nephritis activityand the serum level of soluble VCAM-1. Lupus 1998, 7(5):347-354.
126. Singh S., Wu T., Xie C., et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther 2012, 14(4):R164.
127. Goodsaid F., Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 2007, 9(1):E105-E108.
128. Goodsaid F.M., Frueh F.W., Mattes W. Strategic paths for biomarker qualification. Toxicology 2008, 245(3):219-223.
129. Mina R., von Scheven E., Ardoin S.P., et al. Consensus treatment plans for inductiontherapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012, 64(3):375-383.
130. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum 2004, 50(11):3427-3431.
131. Pons-Estel G.J., Alarcon G.S., McGwin G., et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnicUS cohort. Arthritis Rheum 2009, 61(6):830-839.
132. Henderson L., Masson P., Craig J.C., et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012, (12). CD002922.
133. Henderson L.K., Masson P., Craig J.C., et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013, 61(1):74-87.
134. Sundel R., Solomons N., Lisk L. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 2012, 21(13):1433-1443.
135. Lehman T.J., Sherry D.D., Wagner-Weiner L., et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. JPediatr 1989, 114(6):1055-1060.
136. Daleboudt G.M., Reinders M.E., den Hartigh J., et al. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus 2013, 22(2):171-179.
137. Sagcal-Gironella A.C., Fukuda T., Wiers K., et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2011, 40(4):307-313.
138. Sherwin C.M., Fukuda T., Brunner H.I., et al. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet 2011, 50(1):1-24.
139. Swan J.T., Riche D.M., Riche K.D., et al. Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. JInvestig Med 2011, 59(2):246-258.
140. Gunnarsson I., Sundelin B., Jonsdottir T., et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007, 56(4):1263-1272.
141. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8(3):R83.
142. van Vollenhoven R.F., Gunnarsson I., Welin-Henriksson E., et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004, 33(6):423-427.
143. Fra G.P., Avanzi G.C., Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003, 12(10):783-787.
144. Jonsdottir T., Zickert A., Sundelin B., et al. Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology(Oxford) 2013, 52(5):847-855.
145. Rovin B.H., Furie R., Latinis K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64(4):1215-1226.
146. Manzi S., Sanchez-Guerrero J., Merrill J.T., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domainsin patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012, 71(11):1833-1838.
147. Dhaun N., Kluth D.C. Belimumab for systemic lupus erythematosus. Lancet 2011, 377(9783):2079-2080. [author reply: 2080-1].